Cellular Origins Completes Series A Financing Round
The raised funds, totaling USD 40 million, will be used to accelerate the company’s growth and to advance its robotic platform, Constellation, which enables flexible, scalable cell therapy manufacturing.
Cellular Origins — a TTP company with the mission of industrializing cell therapy manufacturing through advanced automation — has completed its Series A financing round, in which it raised USD 40 million (EUR 34.4 million). The over-subscribed financing round was led by Johnson & Johnson — through its corporate venture capital organization, Johnson & Johnson Innovation — and the syndicate includes Highland Europe, BGF, NYBC Ventures, and TTP Group.
With the funds raised, Cellular Origins will grow its commercial team so that it can deliver on the increasing demand for its Constellation platform, which is a mobile robotic ecosystem for scalable cell therapy manufacturing. Additionally, Cellular Origins will use the funds to broaden the range of unit operations integrated into its platform, giving cell therapy developers confidence that the biological performance won’t be compromised when scaling manufacturing.
Further, Cellular Origins will use the investment to build the systems and infrastructure needed for full manufacturing and services scale up and to create the robust global operation that it will need to meet large-scale demand. In the future, the company will broaden its capabilities to the encompass the wider advanced therapies medicinal products sector.
“This fundraise is a pivotal milestone in our mission to industrialize cell therapy manufacturing,” said Edwin Stone, CEO, Cellular Origins, in a company press release (1). “The support from our investors is a strong endorsement of both our technology and the urgent need for scalable, automated solutions in this space. It recognizes the progress that Cellular Origins, its partners and customers have collectively made towards enabling access to cell therapies at scale. This investment gives us access to the capital and networks to drive our next phase of growth. Through this fundraise we will accelerate the development and deployment of our robotic platform to help make life-saving cell therapies more accessible, reliable, and affordable.”
“Cellular Origins is yet another wonderful spin-out from TTP Group, who have a tremendous track record of success. As a leader in the robotics market and scalable cell therapy manufacturing, Cellular Origins will have a crucial and essential role to play in the commercialization of cellular therapeutics,” added Laurence Garrett, General Partner, Highland Europe, in the press release (1). “We are delighted to be investing in this round and involved with the team as they build the systems and infrastructure needed to meet global demand.”
“This investment is a strong endorsement of the Cellular Origins team and of TTP Group’s track record in creating and growing impactful new businesses,” commented Sam Hyde, CEO, TTP Group, in the press release (1). “Conceived to meet a critical need in advanced therapy manufacturing, the Constellation platform has the potential to transform cell therapy production, and we are proud to continue to support Cellular Origins as it enters this next phase of growth.”
Reference
Cellular Origins. Cellular Origins Closes USD 40 Million in Over-Subscribed Series A Round. Press Release, Dec. 9, 2025.